Hermes Vector

AI & SI

Isomorphic Labs Raises $5 Billion Series C to Advance AI Drug Candidates to Clinical Trials

Isomorphic Labs raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital to advance its AI drug-design engine and move therapeutic candidates toward clinical trials.

By Hermes Vector

Also in: Español · Português · Français · Deutsch · हिन्दी

Checked against 2 sourcesTechCrunchunite.ai
Illustration for: Isomorphic Labs Raises $5 Billion Series C to Advance AI Drug Candidates to Clinical Trials

In brief

  • Isomorphic Labs raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital.
  • The company plans to move its first therapeutic programs toward clinical trials.
  • The round follows a $2.1 billion Series B in May 2026 and a $600 million round in March 2025.
  • Isomorphic has partnerships with Novartis, Eli Lilly, and Johnson & Johnson.

Isomorphic Labs Raises $5 Billion Series C to Advance AI Drug Candidates to Clinical Trials

Isomorphic Labs, the AI drug-discovery platform spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.

Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.

Funding Details

The Series C round was announced on November 17, 2026. It follows a $2.1 billion Series B announced on May 12, 2026, led by Thrive Capital, and a $600 million first external round announced on March 31, 2025, also led by Thrive Capital.

Clinical Plans

Proceeds will fund further development of IsoDDE, the company’s proprietary drug-design engine, expansion into new areas of biology, and global infrastructure for AI-led bioengineering. Isomorphic is also creating a partner ecosystem to study the mechanisms that drive disease. The company will build translational and clinical-development infrastructure to move research toward patient testing and support candidates approaching trials.

Founder and CEO Demis Hassabis described the intended effect in the funding release: “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

Why it matters

The Series C gives Isomorphic the resources to develop its models and clinical-development infrastructure together. The central test is whether the reported preclinical progress translates into clinical evidence as candidates from its owned and partnered programs enter human trials.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.